A Study to Determine the Improvement of the Symptoms of Benign Prostatic Hyperplasia (BPH) When Switching Subjects From Proscar to Avodart
Information source: Urologic Consultants of Southeastern PA
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Benign Prostatic Hyperplasia
Intervention: Dutasteride (Drug)
Phase: Phase 4
Status: Enrolling by invitation
Sponsored by: Urologic Consultants of Southeastern PA
Summary
Hypothesis: Dutasteride will perform better than finasteride in decreasing prostate volume,
improving symptoms based on International Prostate Symptom score,and lower pvr based on the
scientific information that dutasteride inhibits both Type I and II 5-alpha-reducatase vs.
finasteride which only inhibits the Type II enzyme
Clinical Details
Official title: Switch Study: Are There Any Measurable Differences When Switching Patients on Finasteride Therapy to Dutasteride?
Study design: Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Laboratory parameters: including serum testosterone, DHT level and PSA
Secondary outcome: volume measurements of TRUSP and PVRA decrease in the AUASI
Eligibility
Minimum age: 50 Years.
Maximum age: 80 Years.
Gender(s): Male.
Criteria:
Inclusion Criteria:
- Male
- Age 50-80
- On finasteride for no less than 12 months
- Willing to undergo all necessary test in the 12 month evaluation
Exclusion Criteria:
- History of medication non-compliance
- Unwillingness to undergo/tolerate 2 blood draws
- Unwillingness to tolerate/undergo 2 TRUSP
Locations and Contacts
Urologic Consultants of Southeastern PA, Bala Cynwyd, Pennsylvania 19004, United States
Additional Information
Starting date: May 2008
Last updated: June 4, 2008
|
